Eton Pharmaceuticals Reports Strong Q4 & FY25 Results, Projects >$110M Revenue in 2026 with New Product Launches
ETON sits 89% above its 52-week low of $11.087 on elevated volume (2.7× avg).
Summary
Eton Pharmaceuticals reported strong Q4 and full-year 2025 financial results, including significant revenue growth and a return to Q4 net income, alongside robust 2026 guidance driven by new product launches and pipeline advancements.
Key Events · Earnings and Guidance · ETON
-
Strong Q4 and Full-Year 2025 Financial Performance
Eton Pharmaceuticals reported Q4 2025 product sales of $21.3 million, an 83% increase over Q4 2024, and full-year 2025 total revenue of $80 million, more than doubling 2024 revenue. The company achieved net income of $1.5 million in Q4 2025, a significant improvement from a net loss in the prior year period, and Adjusted EBITDA grew 195% to $6.2 million.
-
Robust 2026 Revenue and Profitability Guidance
Management expects full-year 2026 revenue to exceed $110 million, representing substantial growth from 2025, and projects an Adjusted EBITDA margin of over 30%, signaling strong anticipated profitability.
-
Successful Launch of DESMODA™
The company launched DESMODA™, the first and only FDA-approved desmopressin oral solution, on March 9th, with potential peak annual sales estimated between $30-50 million.
-
Strategic Acquisition of Orphan Drug HEMANGEOL®
Eton acquired U.S. rights to the Orphan Drug HEMANGEOL®, establishing a new pediatric dermatology call point and expecting the acquisition to be accretive to 2026 earnings, with a relaunch scheduled for May 1st.
Analysis · ETON · Life Sciences
Eton Pharmaceuticals delivered a strong fourth quarter and full-year 2025, marked by significant revenue growth and a return to net income in Q4. The company's product sales surged 83% year-over-year in Q4 2025, contributing to a doubling of total revenue for the full year. Management provided robust 2026 guidance, projecting revenues to exceed $110 million with an Adjusted EBITDA margin of over 30%, indicating continued strong growth and profitability. Key drivers for this positive outlook include the recent launch of DESMODA™, an FDA-approved oral solution with significant peak sales potential, and the strategic acquisition of U.S. rights to the Orphan Drug HEMANGEOL®. Additionally, the company is advancing several pipeline programs, including label expansions for INCRELEX and KHINDIVI, and a pilot study for ET-700, further strengthening its long-term growth prospects.
At the time of this filing, ETON was trading at $20.94 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $557M. The 52-week trading range was $11.09 to $23.00. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.